Oxford University Hospitals NHS Foundation Trust (John Radcliffe Hospital)
Oxford, Oxfordshire, OX3 9DU, United Kingdom
NCT Number: NCT05608577
The RE-BLEED feasibility study aims to develop and test a real-time digital platform, whereby bleeding patients in-hospital can be identified and approached for their consent to participate in future research studies.
Looking for future studies?
Notify Me16 year–110 year
All sexes
Observational
Oxford, Oxfordshire, OX3 9DU, United Kingdom
Bleeding affects up to 40% of all trauma patients, up to 30% of all surgery patients and is one of the commonest causes of death for women giving birth. The presentation and features of bleeding are different between patients - in some cases bleeding is very obvious to recognise, but in other cases bleeding is more "hidden", for example in the stomach. Bleeding must be stopped promptly to prevent severe illness or death.
Many studies have shown differences in how patients who bleed are treated. There is also variation in how individual patients respond to the same treatment, with some patients doing better than others. Understanding how variation in practice and patient characteristics affect outcomes will help researchers and clinicians design and test improvements in care.
Patients in hospital have regular tests that measure levels of the different types of cells in their blood and its ability to clot. For example, a drop in red blood cells can indicate that patients have suffered bleeding. More advanced blood tests are available that can provide more detailed information on why patients are bleeding and what treatments might be most effective.
This study aims to develop a real-time, hospital-wide digital system to identify patients in hospital who have suffered from bleeding and test whether this system could be used in the future to potentially identify patients to recruit into trials of new treatments or blood tests.
To do this, the investigators will:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Retrospective cohort:
Prospective cohort:
Exclusion criteria
Both retrospective and prospective cohorts:
Time frame: Within 3 months from start of recruitment
Number of patients identified who consent for their blood samples to be retained and analysed as a percentage of those correctly identified as having suffered bleeding by the REBLEED system.
An acceptable recruitment rate is defined as at least 20%, from a total of at least 200 patients correctly identified as having suffered bleeding by the REBLEED system.
Patients correctly identified as having suffered bleeding by the REBLEED system is defined as: Flagged by REBLEED system as potentially having suffered bleeding AND confirmed as having suffered bleeding by research nurse review of electronic medical records
University of Oxford
Other
Acronym: RE-BLEED
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06742801
Digestive System Diseases, GI Bleed
Phoenix, Arizona, United States
View Trial DetailsNCT03572309
Cardiovascular Diseases, Coagulopathy
Brno, Czechia
View Trial DetailsNCT02926274
Cardiovascular Diseases, Coagulopathy
Los Angeles, California, United States
View Trial DetailsNCT04667468
Hemorrhage, Pathologic Processes
Los Angeles, California, United States
View Trial Details